Actively Recruiting
Evaluation of Zilovertamab Vedotin Safety and Efficacy in Children and Young Adults with Blood Cancers and Solid Tumors
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-30
90
Participants Needed
71
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating zilovertamab vedotin for its safety and effectiveness in children and young adults aged 6 to 25 years who have certain blood cancers such as B-cell acute lymphoblastic leukemia B-ALL, diffuse large B-cell lymphoma DLBCLBurkitt lymphoma, or solid tumors including neuroblastoma and Ewing sarcoma. This phase 12 study aims to better understand how well this treatment works and its safety profile in these pediatric and young adult patients with relapsed or refractory disease. Participants receive escalating doses of zilovertamab vedotin through intravenous infusion on the first day of each 21-day treatment cycle. The study involves a single group where all participants are given the study drug, and dosing adjustments are made based on tolerability and response. Treatment may continue across multiple cycles up to approximately 54 months, with assessments for dose-limiting toxicities, adverse events, and treatment responses. Throughout the study, participants undergo regular monitoring including blood tests to measure drug levels, safety labs, and evaluations of disease response. Outcome measures include the number of participants experiencing adverse events, dose modifications, and objective response to treatment. Long-term safety and effectiveness are tracked over the course of the study, which may last up to several years, ensuring careful observation of treatment impact and participant well-being.
CONDITIONS
Brief Title
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here